Introduction the emergence of multidrug-resistant (MDR) strains of
Mycobacterium tuberculosis is one of the most critical issues facing tuberculosis (tB) researchers and clinicians today. patients infected with drug resistant strains are less likely to be cured, and their treatment is more toxic and expensive than the treatment for patients infected with susceptible organisms. inadequate and/or interrupted therapy allows the selection of spontaneous mutations in favor of resistant organisms while sequential acquisition of these mutations in different genome loci results in the development of resistance to multiple drugs.
the situation with MDR-tB in Bulgaria has slightly improved in recent years, although the country together with Romania remains a hot spot of MDR-tB in the european union (except for the Baltic states whose special situation is due to their Soviet past, and cyprus) (24) . For example, the rates of MDR-tB among newly diagnosed and retreatment cases for Bulgaria were reported to be 1.7% and 17.1%, respectively (4.3 and 27.2% for Romania).
The standard DOTS treatment course comprises the five first-line drugs: rifampin (RIF), isoniazid (INH), streptomycin (StR), ethambutol (eMB), and pyrazinamide (pZA). MDR Mycobacterium tuberculosis strains are defined as those resistant to two major first-line anti-TB drugs, rifampin (RIF) and isoniazid (inh) (45) . the mutation rate for RiF is the lowest compared to other drugs' mutation rate (10 -9 versus 10 -8 -10 -7 ), and hence RiF resistance is assumed as a surrogate marker of MDR (13) . however, a geographical variation in the susceptibility profiles is observed which implies that resistance to other drugs besides RiF and inh should be tested as well.
Molecular basis of M. tuberculosis drug resistance
Multiple genes responsible for conferring resistance to the major anti-TB drugs have been identified for M. tuberculosis. A majority of RiF resistant strains harbor mutations in the 81-bp hot-spot region (rifampin resistance determining region, RRDR) of the rpoB gene (45, 55) . inh resistance is controlled by a complex genetic system that involves several genes, katG, inhA, ahpC, kasA, and ndh (23, 26, 45, 51, 64) . Resistance to pyrazinamide (pZA) is usually caused by mutations in the gene pncA encoding pyrazinamidase that converts pZA prodrug to its bioactive form (45) . Resistance to eMB is often caused by the mutations in the embB gene, whose product arabinosyl transferase is involved in mycolic acids metabolism (56) . Mutations in particular sites of the rrs (16S rRnA) and rpsL (small ribosomal protein S12) genes were shown to confer StR resistance in up to 80% of Str r M. tuberculosis isolates (12, 31). in 20-25% of Str r and emb r strains the resistance associated mechanism remains unknown (31, 45) . noteworthy, not all mutations are invariably indicative for resistant pathogens and may instead play either a minor role in conferring lowlevel resistance (31, 45) , or represent a natural polymorphism reflecting neutral evolution, relevant for phylogenetic studies (52, 62) .
DRUG-RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS: MOLECULAR BASIS AND GENOTYPIC DETECTION
Resistance to RiF in M. tuberculosis has been associated with mutations in rpoB, the gene encoding the beta-subunit of the DnA-dependent RnA polymerase, the main target of RiF (55) . it has been demonstrated in many studies that 95 to 98% of resistant isolates have mutations in rpoB, while 90-95% of them are located in the 81-bp hot-spot region (45), codons 507-533 (Escherichia coli codon numbering system (55)). in spite of the fact that multiple mutations in this short region were found, most of them were described in three rpoB codons: 516, 526, or 531. Mutations in these codons accounted for the majority (70-95%) of RiF-resistant strains, especially in the areas with high rate of MDR-tB (reviewed in (6, 32, 45, 63) ). Also, a mutation V176F located at the beginning of rpoB gene was recently described in 2% of RiF-resistant isolates from Germany (18) .
in Bulgaria, a very high rate of the rpoB S531l (tcG>ttG) mutation was found in our recent study (57) . A similar situation was described, e.g., for Russia and Kazakhstan, but it was associated with a Beijing genotype (19, 35) . in other studies, rpoB 531ttG allele was found at a similar rate of ~50% in the Beijing versus non-Beijing RiF-resistant strains from east Asia (21, 38) . A variation in the prevalence of this rpoB S531l mutation among Beijing strains in different countries may reflect not only the increased capacity of the Beijing family strains to readily acquire the most frequently observed rpoB mutation but also some specific features of the National TB control programs in different countries (3, 50) . in our study the Beijing genotype was not found in Bulgaria among the 133 clinical isolates studied, hence the current situation with MDRtB in Bulgaria cannot be explained by global dissemination of the Beijing genotype that apparently has not yet reached this country (57, 58) .
the inhA, enoyl-Acp-reductase, a protein involved in mycolic acids and subsequent cell wall biosyntheses, was identified as a main target of INH, and the mutations linked to the inh resistance phenotype were described in two regions of the inhA locus. the mutations in the putative promoter region upstream orf1-inhA are thought to increase the inhA protein expression, thereby elevating the drug target levels and producing inh resistance by a drug titration mechanism (30) . the inhA mutations which change the nADh binding site of inhA most affected by inh, were also described in resistant isolates (48) . two other genes related to inh resistance have recently been suggested: the kasA gene encoding another inh target, beta-ketoacyl-Acp-synthase and the regulatory region of the ahpC gene encoding alkyl-hydroperoxidase. Mutations in these genes seem to provide a supplementary mechanism of resistance and need further investigation (23, 53) . Finally, extensive studies have demonstrated that inh resistance is most frequently associated with mutations in katG. the inh used for therapy is a prodrug that requires catalytic activation. catalase-peroxidase, the product of the katG gene was shown to accomplish this task, and the mutations in this gene mediate inh resistance (45) . early studies showed that complete or large deletions of the gene are rare, since the peroxidase activity in the KatG protein is necessary to detoxify host antibacterial radicals (14, 42, 45) . For this reason, the predominant way of acquiring resistance via KatG alterations is through a selection of those particular mutations that decrease catalase activity but maintain the peroxidase activity of the enzyme at a certain level in viable inh-resistant organisms. Such mutations were found in up to 90% of inh-resistant strains, and one particular substitution in codon 315, AGc>Acc (Ser>thr), was reported as the most frequent, apparently providing the optimal balance between the decreased catalase and sufficiently high peroxidase activities of KatG. this mutation was reported to be associated with intermediate or high levels of resistance to inh (1 to 10 μg/ml (45, 61) ). The prevalence of the katG315 AGc>Acc mutation among inh-resistant M. tuberculosis strains in the world, though generally high, varies in regions with low and high tB incidences, ranging from rare occurrences in Finland (28) to 26-30% in Singapore (25) , 64% in South Africa (60), 79% in peru (10) and 93% in Russia (33, 35) . A large-scale study of hazbon et al. (17) showed that mutations in katG315 were significantly more common in the multidrug-resistant isolates while mutations in the inhA promoter were significantly more common in inh-monoresistant isolates. the prevalence of the katG315 AGc>Acc mutation among inh-resistant M. tuberculosis strains in the world varies but continues to remain high, e.g., 47% in Finland (29) , 61% in china (20) , 64% in india (41), 93% in Russia (33) . Accordingly, it appears that katG S315t mutation alone can be used to reliably predict a high proportion of the inh-resistant strains in many world regions. For Bulgaria this is not the case. Surprisingly, only 11 out of 23 inh-resistant strains would be detected genotypically through analysis of the two targeted mutations (57) . Furthermore, inhA mutation was found in only one inh-resistant strain that coharbored a katG315 mutation. three other strains with inhA mutation were inh-susceptible. hazbon et al. (17) observed a strong negative association between mutations in katG315 and mutations in the inhA promoter region (p<0.01). in our study, a Mic was 0.25 mg/l for inh and indeed it may be that the three inh-susceptible strains with inhA promoter mutation (katG315 wild type) had a low-level inh-resistance below the breakpoint used (57) . perhaps, mutations in other parts of the katG gene and in other gene regions such as, ahpC promoter region, inhA coding sequence or other gene, may account for resistance in other inh-resistant isolates in this study.
the major mechanism of acquisition of resistance to eMB in Mycobacterium tuberculosis was shown to be associated with the point mutations in the embCAB operon encoding different arabinosyl transferases (1, 56) . in particular, amino acid replacements at position 306 of embB were shown in many studies to be represented among eMB-resistant, but not eMBsusceptible, organisms (1, 45, 54) . Five different mutations were detected in this codon altering its first or third bases (AtGà GtG, ctG, AtA, Atc, Att) and resulting in three amino acid shifts (Metà Val, leu, ile) (54) . Several additional loci encoding proteins that may participate in the response of M. tuberculosis to EMB treatment have been identified (2) and a an extensive study investigated more genes as related to the development of eMB resistance in tubercle bacilli (46) . however, one fourth of eMB r strains still lacked any known mutation linked to the eMB resistance (46) , implying multiple molecular pathways to its development, and some of them are yet to be discovered. the prevalence of resistance to eMB, initial and acquired, is not generally high and varies in different countries from 1.3% in canada (47) to 23.3% in pakistan (22) , with an overall average of 4-9% for initial resistance (67, 68) , and is predominant among patients with MDR TB. For the first time, Mokrousov et al. (34) highlighted a presence of embB306 mutations in eMB-susceptible strains and hazbon et al. (16) suggested an association of embB306 mutations with broad drug resistance and clustering rather than eMB resistance. our own results on embB306 variation in Bulgarian population of M. tuberculosis (57) are in line with earlier findings (45, 46) and German results (43) which correlated mutations in embB306 with eMB resistance. they are in contradiction with more recently reported discrepancies between genotypic and phenotypic eMB resistance (16, 34 , and references therein). A number of explanations of these contradictory findings have been proposed. plinke et al. (43) suggested that there is a small difference between the critical concentration used for eMB susceptibility testing and the Mic, making susceptibility testing more problematic. Mokrousov et al. (34) hypothesized an unknown mechanism in MDR M. tuberculosis strains that leads to susceptibility to eMB. hazbon et al. (16) suggested that the clear association between mutations in embB306 and eMB resistance found in several earlier studies might be due to the use of pansusceptible strains as control groups. Regarding this latter point, our own study in the Bulgarian setting found embB306 mutation in 7 isolates of which 6 isolates were resistant to more than one drug. indeed, embB306 mutation was not found in fully susceptible or monoresistant isolates (except for one eMB-monoresistant). however all eMBsusceptible MDR isolates in our study had embB306 wild type allele (57) . Accordingly, it appears that a hypothesis of hazbon et al. (16) about embB306 as a marker of multidrug resistance is only partly supported by our data.
Genotypic detection of drug resistant M. tuberculosis
the drug susceptibility test on solid or liquid medium is the standard procedure to establish drug resistance for M. tuberculosis. however, its results are available only 6-8 weeks after sample collection (11) . thus the prediction of drug resistance of M. tuberculosis by molecular tools presents a rapid alternative to the culture-based phenotypic susceptibility tests.
Among genotypic methods used to date are direct sequencing, real-time pcR, microchips technology, pyrosequencing, pcR single strand conformation polymorphism, RnA/RnA mismatch, molecular beacons, reverse hybridization and some other assays. it should be noted that certain resistance linked mutations (katG315 AGc>Acc and rpsL43 AAG>AGG) can be easily detected by the specific PCR-RFLP or allelespecific PCR methodologies (7, 33, 34, 35, 36, 63) . However, such methods targeting alterations in the short gene regions (4-6 bp of the cleavage site) are ineffective for mutations in rpoB, mabA-inhA, ahpC, rpsL88, and rrs, that are scattered throughout more extended regions and/or do not concern actual or potential sites of known restriction endonucleases. in this view, a DnA macroarray approach was suggested promising for simultaneous analysis of multiple alterations in multiple genes (8, 37, 38, 39) . In this method, specific oligonucleotides corresponding to wild-type ("drug susceptible") and mutant ("drug resistant") sequences of a gene are immobilized onto a membrane and subsequently hybridized with biotin/ digoxigenin-labeled PCR-amplified gene fragment; the hybrids are revealed by luminescence or colorimetric immunoenzyme reaction.
the other popular approach to mutation analysis is using real-time pcR in its different variants; methods based on fluorescent hybridization probes have recently been designed for various real-time pcR equipment (9, 11, 27, 59) . Few studies, mostly including only positive samples, have focused on direct detection in clinical samples (27, 59, 66) . in particular, espasa et al. (11) developed and evaluated a method for rapid direct detection in smear-positive and -negative clinical samples, of the main mutations causing isoniazid and rifampicin resistance of M. tuberculosis using real-time amplification and fluorogenic exonuclease TaqMan probes with or without minor groove binder (MGB) modification. The main achievements of their method were the detection of more than one half of the resistance cases in the studied area within 48 h of collection of the clinical samples and that 75% of the cases with drug resistance have genetic target mutations. Most recently, a fully automated version of the multiplex real-time pcR was developed named GeneXpert system using the Xpert MTB/RIF assay (5, 40) . An interesting modification is allelespecific RT-PCR using labeled allele-specific primers (65) .
When evaluating and selecting a method of detection, one should be clear about its advantages and drawbacks. thus the apparent advantage of the real-time pcR as a whole is a possibility to use the same apparatus, in real-time format, in single tube thus decreasing a possibility of contamination. At the same time, a use of several tubes per sample and, eventually, use of different cycling programs increases the turnaround time of analysis. in the study of Vladimirsky et al. (65) , the katG315 and inhA mutations were analysed by MAS-pcR under the same cycling conditions while rpoB531 required use of the other temperature profiling.
in a multicenter study, reverse hybridization macroarray approach (37) was shown useful for detection of most RiF-resistant (rpoB mutations) and eMB-resistant (embB306 mutation), and of certain StR-resistant (rrs513, rpsL88 mutations) and inh-resistant (inhA, ahpC mutations) M. tuberculosis isolates. the method was postulated to be rapid, requiring the same simple equipment as that used for spoligotyping, allowing to analyze up to 40 samples simultaneously, and the results, generally easy to interpret. An advantage of rifoligotyping (reverse hybridization) is a possibility to target the entire 81-bp rpoB region on a single membrane. however, the method takes ~2 days as it includes a pcR/gel-electrophoresis step as well as hybridization, washing and exposure procedures. Furthermore, not all alleles can be analysed using this method, at least its version used here and described elsewhere (37) . For example, katG315 (and rpsL43) mutations could not be detected by this assay: both wild type and mutant probes failed to produce reliable hybridization signals (probably, due to conformational constraints imposed by the ssDnA folding). Furthermore, even if immobilized on the same membrane, different mutations in different genes may require different hybridization conditions hence double use of membrane was needed to analyse the full range of the resistance genes.
Different Rt-pcR studies showed various ways to increase sensitivity of the method. A use of MGB probes permitted van Doorn et al. (59) to achieve a sensitivity of 90% in smear-positive samples and 65% in smear-negative samples. likewise, using nested pcR format and MGB probes to katG315 and rpoB 81-bp region increased sensitivity from 59% to 100% sensitivity (66). Ruiz et al. (49) presented a method based on real-time pcR using FRet probes for detecting inh and RiF resistance in the same genes as those used by espasa et al. (11) and found sensitivity from 96.5 to 97.5%, when smear-positive samples were analysed. Marin et al. (27) also used FRet probes for the detection of 13 point mutations, including the rpoB 81-bp region and katG315. With the implementation of this strategy in smear-positive clinical samples, espasa et al. (11) achieved a sensitivity of 100%. Another approach, which combined an initial real-time pcR with internal inhibition assessment and a pyrosequencing assay, was also validated for direct use with clinical specimens and showed good sensitivity of 96.6% (15) .
A geographic variation in the distribution of particular mutations associated with anti-tB drug resistance is frequently observed. At the same time, analysis of a limited number of gene codons allows to predict resistance to main anti-tB drugs for the majority of M. tuberculosis isolates in a high-incidence community (60) . Single codons embB306, katG315 and a minimum of three rpoB codons -516, 526, 531, are required to detect reliably eMB-, inh-, and RiF-resistance, respectively. particular methods used so far for detection of embB306, katG315 and rpoB mutations include DnA sequencing, pcR-single strand conformation polymorphism, RnA/RnA mismatch, dot-blot hybridization, molecular beacons, pcRRFlp (for katG315 and embB306), and line probe (for rpoB) assays, microchips technology, and some other methods (reviewed in (7, 63) ).
therefore, a preliminary evaluation of a new diagnostic tool with a representative sample from a survey area is preferable prior to a larger-scale implementation into routine practice. the inherent sensitivity limit of genotypic methods to detect RiF, inh, and eMB resistance is explained by the fact that a certain number of isolates have other resistance mechanisms untargeted by these methods -up to 10-15%% in some rpoB studies (4, 35, 36, 37, 44) . therefore the molecular methods cannot completely substitute culture-based phenotypic tests but may successfully complement them. For example, rpoB RRDR and embB306 mutations may serve for rapid genotypic detection of the majority of the RiF and eMB-resistant M. tuberculosis strains in Bulgaria. the results for inh resistance were complex and further investigation of more genes is needed (57) . A local circulation of the particular clones appears to be an important factor to take into consideration in the molecular epidemiological studies of tuberculosis in Bulgaria. emergence and spread of drug-resistant and MDR-tB in Bulgaria are not associated with any particular spoligotype or MiRu-VntR genotype.
